|1.||Rosenson, Robert S: 7 articles (12/2012 - 09/2010)|
|2.||Hislop, Colin: 5 articles (02/2012 - 09/2010)|
|3.||Fraser, Heather: 2 articles (12/2011 - 10/2010)|
|4.||Stasiv, Yuri: 2 articles (04/2011 - 09/2010)|
|5.||Elliott, Michael: 2 articles (04/2011 - 09/2010)|
|6.||Hurt-Camejo, Eva: 1 article (12/2012)|
|7.||Kastelein, John J P: 1 article (02/2012)|
|8.||Bash, Dianna: 1 article (02/2012)|
|9.||Cavender, Matthew A: 1 article (02/2012)|
|10.||Schwartz, Gregory: 1 article (02/2012)|
|1.||Acute Coronary Syndrome
02/01/2012 - "The VISTA-16 study will determine whether varespladib methyl has a beneficial impact on cardiovascular events in patients with an acute coronary syndrome."
12/01/2011 - "Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome."
02/01/2012 - "Up to 6,500 patients with acute coronary syndrome will be randomized to receive treatment with varespladib methyl 500 mg daily or placebo for 16 weeks, in addition to background treatment with atorvastatin and other evidence-based therapies. "
01/01/2011 - "Anthera Pharmaceuticals is developing an oral formulation of varespladib (A 001; A 002; A-001; A-002; LY 315920; LY 333013; LY315920; LY333013; S 3013; S 5920; S-3013; S-5920; Varespladib methyl) for once-daily treatment of acute coronary syndromes. "
10/01/2010 - "The experimental basis for sPLA(2) inhibition with varespladib methyl as a potential candidate for lowering recurrent cardiovascular events particularly in acute coronary syndrome patients is discussed. "
|2.||Coronary Artery Disease (Coronary Atherosclerosis)
01/01/2011 - "In order to achieve the widespread use of varespladib methyl in ACS patients, completion of a prospective, randomized placebo-controlled trial in ACS patients and stable coronary artery disease patients with increased sPLA(2) activity will be required."
09/01/2009 - "Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease."
09/01/2009 - "Phase II clinical trials of varespladib methyl in patients with coronary artery disease, rheumatoid arthritis, asthma and ulcerative colitis revealed that the drug was well tolerated. "
09/01/2009 - "Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the potential treatment of coronary artery disease, acute coronary syndrome and inflammation. "
09/01/2009 - "Varespladib methyl did not demonstrate a good efficacy profile in patients with rheumatoid arthritis, asthma and ulcerative colitis, whereas in patients with coronary artery disease, varespladib methyl consistently reduced LDL-cholesterol levels (elevated LDL-cholesterol levels are a marker of increased cardiovascular risk). "
04/01/2011 - "Phospholipase Levels And Serological Markers of Atherosclerosis II (PLASMA II) is a Phase II, randomized, double-blind, placebo-controlled parallel-arm study of two once-daily doses of the novel sPLA(2) inhibitor, 1-H-indole-3-glyoxamide or varespladib methyl (Anthera Pharmaceuticals, Hayward, CA, USA). "
02/01/2012 - "The Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16, NCT01130246) tests the hypothesis that varespladib methyl, an inhibitor of several sPLA(2) isoforms with a causal role in atherosclerosis, reduces cardiovascular risk among patients with acute coronary syndromes. "
|4.||Coronary Disease (Coronary Heart Disease)
04/01/2011 - "One hundred and thirty-five stable coronary heart disease patients were treated with either varespladib methyl 250 mg once daily, varespladib methyl 500 mg once daily, or placebo for 8 weeks. "
12/01/2012 - "A clinical trial with the sPLA(2) inhibitor varespladib methyl was recently terminated, while clinical trials with the Lp-PLA(2) inhibitor darapladib are being conducted in coronary heart disease patients. "
|5.||Cardiovascular Diseases (Cardiovascular Disease)
09/01/2009 - "Varespladib methyl could represent a novel therapy for the treatment of cardiovascular disease, although the efficacy, safety profile and advantages of this drug compared with existing therapeutic options would need to be established in upcoming phase III trials."
10/01/2010 - "Varespladib methyl in cardiovascular disease."
|1.||Secretory Phospholipases A2
|2.||Biological Markers (Surrogate Marker)
|5.||1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)
|8.||Protein Isoforms (Isoforms)